PT  - JOURNAL ARTICLE
AU  - de León, Ugo Avila-Ponce
AU  - Avila-Vales, Eric
AU  - Huang, Kuan-lin
TI  - Modeling the transmission of the SARS-CoV-2 delta variant in a partially vaccinated population
AID  - 10.1101/2021.09.23.21264032
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.23.21264032
4099  - http://medrxiv.org/content/early/2021/09/26/2021.09.23.21264032.short
4100  - http://medrxiv.org/content/early/2021/09/26/2021.09.23.21264032.full
AB  - In a population with ongoing vaccination, the trajectory of a pandemic is determined by how the virus spreads in unvaccinated and vaccinated individuals that exhibit distinct transmission dynamics based on different levels of natural and vaccine-induced immunity. We developed a mathematical model that considers both subpopulations and immunity parameters including vaccination rates, vaccine effectiveness, and a gradual loss of protection. The model forecasted the spread of the SARS-CoV-2 delta variant in the US under varied transmission and vaccination rates. We further obtained the control reproduction number and conducted sensitivity analyses to determine how each parameter may affect virus transmission. Our results show that a combination of strengthening vaccine-induced immunity and preventative behavioral measures will likely be required to deaccelerate the rise of infectious SARS-CoV-2 variants.One-Sentence Summary Mathematical models considering vaccinated and unvaccinated individuals help forecast and manage the spread of new SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUgo Avila Ponce de Leon also received a fellowship (CVU: 774988) from Consejo Nacional de Ciencia y Tecnologia (CONACYT). KH received funding from ISMMS and NIH NIGMS R35GM138113. This article was supported in part by Mexican SNI under CVU 15284.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was not required since the work used only publicly available dataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe original contributions presented in the study are included in the article/Supplementary Material. All code used for analysis is available https://github.com/UgoAvila/Delta-Variant-In-the-US. https://github.com/UgoAvila/Delta-Variant-In-the-US